[The results of a clinical trial of the new drug agent carbabenzpyride]. / Rezul'taty klinicheskogo ispytaniia novogo lekarstvennogo sredstva karbabenzpirida.

Analyzed were results of a clinical use of a new drug carbabanzpyrid in 57 patients as an analgetic, antipyretic, anti-inflammatory, interferonogenic drug. The drug proved effective in the complex treatment of several diseases, accompanied by fever, pain syndromes of different genesis and location, acute respiratory viral infections, active inflammatory processes of different etiology including bronchitis, pneumonia, active rheumatism, arthralgias, myalgias. The drug was of little efficacy in infections-allergic polyarthritis with a marked exudative component.

[Beta-adrenoblockaders and calcium antagonists in the treatment of patients with ischemic heart disease combined with hypertension]. / Beta-adrenoblokatory i antagonisty kal'tsiia v lechenii bol'nykh ishemicheskoi bolezn'iu serdtsa v sochetanii s gipertonicheskoi bolezn'iu.

The authors studied 67 patients with ischemic heart disease associated with hypertensive disease and revealed that the use of beta-adrenoblockaders and calcium antagonists resulted in a reduction of the manifestations of the disease, increase of physical load tolerance, optimization of its hemodynamic and oxygen provision. In patients under 60 years of age of beta-adrenoblockaders resulted in an increase of the myocardial contractility. This was not observed in those over 60 years of age. It is concluded that in patients combining IHD with hypertensive disease under 60 it is more preferable to use beta-adrenoblockers, in those over 60--calcium antagonists.